Kiora Pharmaceuticals, Inc.
KPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.01 | 0.02 | 2.68 |
| FCF Yield | 66.93% | -377.95% | -46.13% | -8.19% |
| EV / EBITDA | 1.59 | -0.01 | -1.23 | -8.87 |
| Quality | ||||
| ROIC | 9.39% | -103.81% | -78.70% | -75.32% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 2.38 | 0.76 | 0.77 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 189.49% | 8.35% | 2.90% | -46.37% |
| Safety | ||||
| Net Debt / EBITDA | -0.66 | 0.19 | 0.43 | 0.55 |
| Interest Coverage | 210.31 | -1,130.69 | -1,431.51 | -2,077.91 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 13.71 | 0.00 | 0.00 | 0.00 |